The DNMT-inhibitors 5-azacitidine (5-AC) and 5-aza-2’-deoxycytidine (DAC) are FDA-approved for the treatment of hematological malignancies and myelodysplastic syndrome. This evidence concerns the gene DNMT1 and hematologic disorder.